Cassava sciences reports q2 2023 financial results and operating updates

Austin, texas, aug. 03, 2023 (globe newswire) -- cassava sciences, inc. (nasdaq: sava), a clinical-stage biotechnology company focused on alzheimer's disease, today announced financial results for the second quarter ended june 30, 2023. net loss was $26.4 million, or $0.63 per share, compared to a net loss of $19.3 million, or $0.48 per share, for the same period in 2022. net cash used in operations was $33.2 million during the first half of 2023. net cash use in second half 2023 is expected to be $40 to $50 million, driven primarily by expenses for our clinical program in alzheimer's disease.
SAVA Ratings Summary
SAVA Quant Ranking